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Abstract
Background: Cyclooxygenase 2 (COX-2) is an inducible isoform by cellular activation, proinflammatory cytokines
and growth factors. The aims of the current study were to evaluate COX-2 immunoexpression in epithelial and
lamina propria (LP) of cats with inflammatory bowel disease (IBD) and low grade alimentary lymphoma (LGAL), as
well as to correlate them with clinical signs and histopathological scoring. Cats diagnosed with IBD and LGAL
(2007–2013) were included in the current study. Feline chronic enteropathy activity index (FCEAI) was calculated
for all cases. Control group was composed by 3 healthy indoor cats and 5 sick cats died or were euthanized
(non-gastrointestinal illness). Diagnosis and classification of IBD and LGAL was established according to the WSAVA
gastrointestinal standardization group template and the National Cancer Institute formulation, respectively. Furthermore,
a modified WSAVA template was applied for LGAL evaluation. Immunolabelling for COX-2 (polyclonal rabbit anti-murine
antibody) was performed on biopsy samples. Epithelial and LP (inflammatory or neoplastic cells) COX-2 immunolabelling
was calculated according to the grade and intensity. The most representative segment scored by the WSAVA and the
modified WSAVA were used for statistical analysis.
Results: Significant difference was found regarding COX-2 intensity overexpression in the epithelial cells of IBD and
LGAL groups when compared to control cats, but not between the groups of sick cats, whereas no differences
were found regarding the grade of immunoreactivity between groups. No difference was found for COX-2
immunoexpression at the LP between all groups. However, 3 cats from LGAL group showed COX-2 expression in
neoplastic cells at the LP. There were no correlations between epithelial or LP COX-2 expression and FCEAI and
histological alterations.
Conclusions: Increased COX-2 intensity at the epithelial cells observed in cats with IBD and LGAL may be secondary
to the inflammatory response or a protective function in the intestinal reparation. COX-2 expression at the LP was
presented in 33% of LGAL. This result provides a reason for further investigation concerning the role of COX-2
expression in feline alimentary lymphoma.
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Background
Inflammatory bowel disease (IBD) and low grade alimen-
tary lymphoma (LGAL) are common causes of chronic
enteropathies (CEs) in cats [1–6]. IBD is a chronic
immune-mediated disease whose cause remains unknown
but is likely multifactorial [1–3, 6]. Currently, alimentary
lymphoma (AL) is the most common anatomic form of
lymphoma and its cause is also unknown [5, 7–12]. IBD
and LGAL can affect any segments of the gastrointestinal
(GI) tract and clinical differentiation between them may be
a challenge. Therefore histopathological diagnosis is always
needed though overlapping may also occur, complicating
the definitive diagnosis [3, 5, 13–16]. In addition, evolution
from chronic intestinal inflammation to AL has been pro-
posed in cats but definitive proof is lacking [9, 17].
Cyclooxygenase 2 (COX-2) is an inducible inflamma-
tory regulator isoform by cellular activation, proinflam-
matory cytokines, growth factors, tumour promoters and
prostaglandin mediator [18–21]. Prostaglandin E2, a
COX-2 metabolite, has many biological roles including
mediating pain, modulation of cytokine production, in-
duction of regulators of angiogenesis, production of pro-
inflammatory mediators and promotes tumourigenesis
[22, 23]. Furthermore, overexpression of COX-2 may be
a consequence of inflammation leading to increased
levels of Bcl-2 and resistance to apoptosis of the cells,
thus enhancing the risk of cancer [24, 25]. To the au-
thor’s knowledge, there is only one available study in
cats that included 6 cases of intestinal lymphoma and
described negative COX-2 immunoexpression [26], and
there is no study describing COX-2 immunoexpression
in feline IBD and LGAL.
The aim of the present study was to evaluate COX-2
immunoexpression at the epithelium and lamina propria
(LP) of cats with IBD and LGAL. The second objective
was to correlate the COX-2 immunolabelling with clin-
ical signs and histopathological scoring.
Methods
Study population
Control group was composed of 3 healthy control indoor
female cats (HCC, median age = 2 years; range = 1–5 years)
owned by the personal staff were submitted to endoscopy
prior to ovariohysterectomy and duodenal biopsies were
obtained, and 5 sick cats (SC, median age = 7 years; range
= 1–18 years) who died or were euthanized for unrelated
GI diseases and full thickness biopsies (FTB) from duode-
num, jejunum and ileum were obtained within 1 h. Cats
had not received glucocorticoids (GC), chemotherapy,
non-steroidal anti-inflammatory drugs (NSAIDs) or anti-
biotics with immunomodulatory action such as doxycyc-
line and azithromycin previously. All these cats were
recruited from the Fundació Hospital Clínic Veterinari of
the Universitat Autònoma de Barcelona.
Approval consent was signed and accepted by the
owners and procedures were approved by the Ethical
Committee from the Faculty of Veterinary Medicine
and Bioscience Engineering of Universitat Autònoma
de Barcelona (CEAAH 2354).
IBD and LGAL cases of the study were collected be-
tween 2007 and 2013 from the Fundació Hospital Clínic
Veterinari of the Universitat Autònoma de Barcelona.
The inclusion criteria was the presence of chronic GI
signs (> 3 weeks duration), complete medical history and
no previous GC, chemotherapy, NSAIDs or antibiotics
with immunomodulatory action treatments 6 months
before the presentation. Information obtained from all
cats included signalment (age, breed, sex, body weight),
history, physical examination, clinicopathological testing
(complete blood count, biochemistry profile and total T4
and abdominal ultrasonography). All patients were nega-
tive to feline leukaemia virus antigen and immunodefi-
ciency virus antibodies. Cats with mild to moderate
clinical signs were treated at the beginning with antipar-
asitic for 5 days, followed by elimination diet (novel pro-
tein or hydrolysed elimination diets) for at least 14 days
to rule out parasitism and food response enteropathy,
respectively. Posteriorly, endoscopy or FTB were ob-
tained. Otherwise, severely compromised patients were
submitted to intestinal biopsy after blood works and
ultrasonography. These patients did not receive antipar-
asitics or placed on diet trials at presentation, but did
during treatment in cats with IBD. Biopsies were ob-
tained by laparotomy (duodenum, jejunum and/or
ileum) or endoscopy (duodenum). Stomach and colonic
biopsies were not considered in this study. Cats with
extra-GI diseases were excluded from the study.
Chronic enteropathy activity index
The feline chronic enteropathy activity index (FCEAI)
was applied to all studied cats [2]. This index gave a
scoring to GI signs (vomiting, diarrhoea, anorexia,
weight loss, lethargy; 0 to 3 points for each sign accord-
ing to severity), hyperproteinaemia (yes = 1 point, no = 0
point), hypophosphataemia (yes = 1 point, no = 0 point),
increased serum alanine aminotransferase (ALT) and/or
alkaline phosphatase (ALP) activities (yes = 1 point, no =
0 point). Endoscopic lesions parameter was not included
because FTB were performed in most of the cats and en-
doscopy was not repeated. A questionnaire was filled by
the owners at the first visit or phone calls. A composite
score was subsequently calculated yielding values for
mild (2 to 5), moderate (6 to 11) and severe (12 or
greater) CE [27].
Histopathological classification
Biopsy samples were fixed in neutral-buffered formalin
and embedded in paraffin wax. Tissue was sectioned
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(3 μm) and stained with haematoxylin and eosin. Single
board-certified pathologist (AR) reviewed all sections
and was blinded to the clinical information. Previously
published diagnostic algorithm was used to differentiate
IBD from LGAL [16].
Biopsies from the control and IBD groups were evalu-
ated according to the world small animal veterinary as-
sociation (WSAVA) GI Standardization Group template
[28]. This template only assesses the duodenal morpho-
logical features (villous stunting, epithelial injury, crypt
distension, lacteal dilation and mucosal fibrosis) and in-
flammation changes (intraepithelial lymphocytes, LP
lymphocytes and plasma cells, eosinophils, neutrophils,
other cells) from the duodenum. They were scored as
absent = 0, mild = 1, moderate = 2, or severe = 3. Finally,
histologic severity scores were recorded and determined
to be normal (score 0), mild (1–6), moderate (7–13), se-
vere (14–20), and very severe (> 20) [29]. Jejunal and
ileal biopsies were scored according to the WSAVA tem-
plate as Casamian-Sorrosal and colleagues described in
these segments [30].
Modified WSAVA (MWSAVA) score was used for
LGAL cases that included morphological features (vil-
lous stunting, epithelial injury and crypt distension) and
applied to duodenum, jejunum and ileum [31]. These
features were scored as absent = 0, mild = 1, moderate =
2, or severe = 3. Total scores were classified as normal
(score = 0), mild (1–3), moderate (4–6), severe (7–9),
and very severe (> 10) according to a calculated propor-
tion of the classification mentioned above.
LGAL cases were classified according to the National
Cancer Institute working formulation. The number of
mitoses between 0 and 5 at high-power field and small
nuclear size (< 1.5X the size of a red blood cell) corres-
pond to LGAL [32]. Furthermore, CD3 and CD20
immunophenotyping was performed in LGAL and se-
vere IBD cases as previously described [16].
For statistical evaluation, the small intestinal segment
with the higher or modified histological score of each in-
dividual was considered.
COX-2 immunohistochemistry
Sections (3 μm) were routinely deparaffinised, rehy-
drated and antigen retrieval at pH 6 was performed by
PT-Link Automatic System (Dako Glostup, Denmark).
Immunostaining was performed on a Dako Autostainer
Plus, using procedures, buffers and solutions provided
by the manufacturer. Primary antibody binding was
detected with a standard two-layer indirect method (En-
Vision; DakoCytomation). Chromogen staining was devel-
oped with diaminobenzidine. Slides were counterstained
with haematoxylin. The primary antibody (polyclonal
rabbit anti-murine COX-2; Cayman Chemical, Ann Arbor,
Michigan, USA) at a 1 in 500 dilution was used. A rabbit
polyclonal antibody against Leishmania infantum, kindly
provided by Instituto de Salud Carlos III (Madrid, Spain),
was used for negative control purposes (1:3000). Sections
of feline foetal kidney (Fig. 1) and cutaneous squamous cell
carcinoma were used as positive controls [33–35]. COX-2
immunohistochemical staining was performed on a normal
feline lymph node as a negative control.
Epithelial, inflammatory and/or neoplastic cells COX-2
immunolabelling was evaluated by a semi-quantitative
assessment which included staining grade (percentage
of positive cells) and intensity. Five 10X fields from
each slide were evaluated. The grade (percentage) was
evaluated by the following scoring system: 0 = nega-
tive; 1 = < 10% of cells staining positive; 2 = 10–30%; 3 =
31–60%; 4= > 60%. Intensity was evaluated by the fol-
lowing scoring system: 0 = negative; 1 = weak staining;
2 = moderately intense staining; and 3 =marked intense
staining. Intensity of positive control cells was considered
marked staining [26]. The final expression score was cal-
culated multiplying the intensity with percentage and clas-
sified as weak (1–2), moderate (3–5), marked (6–8) and
very marked (> 9).
Statistical analysis
Statistical analysis was performed using SPSS statistics
software (SPSS 17.0 version, Chicago, IL, USA) adopting
a level of significance of p < 0.05. Shapiro-Wilk test were
used for tested normality of the data. Non-parametric
tests were applied for data that did not present a normal
distribution, and median and range were used for sum-
mary. The Kruskal-Wallis test was used to compare con-
tinuous variables (FCEAI, WSAVA and MWSAVA
scores, epithelial and LP COX-2 expression) between
Fig. 1 Macula densa from a foetal kidney showing marked intensity
of COX-2 immunoexpression and apical border of renal tubular cells
expressing moderate intensity
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groups. The Mann-Whitney test was used as post-test
analysis for the evaluation of the variation between the
different groups.
Results
A total of 28 cats met the inclusion criteria but 8 cats
were eliminated because biopsy samples were unavail-
able. Therefore, 11 cats with IBD and 9 cats with LGAL
were studied. The median age was 5 years (range = 2–
12) for IBD group and 12 years (range = 8–15) for the
LGAL group. LGAL group presented a slightly higher
body weight (median = 4.2 kg; range = 3.00–6.26) than
IBD group (median = 3.88 kg; range = 2.00–6.00). All
cats were neutered, except 1 intact female and 1 intact
male from the IBD group. There were 5 (45%) female
and 6 (55%) male cats in the IBD group and 1 (11%) fe-
male and 8 (89%) male cats in the LGAL group. Breeds
represented in the IBD group were Domestic Shorthair
(DSH, 4), Domestic Longhair (3), Siamese (2), Persian
(1) and Norwegian Forest (1) cats. All cats belonging to
the LGAL group were DSH cats.
Endoscopy biopsies were obtained from 3 cats and
FTB from 8 cats of the IBD group. Samples were ob-
tained mostly from the duodenum (9 cats). Regarding
the inflammatory cells infiltration at the LP, 8 cases had
lymphoplasmacytic (73%) and 3 eosinophilic (27%) in-
flammation. FTB were collected in all cats with LGAL
except for 1 patient. All LGAL animals were T cell
lymphoma and it was most commonly diagnosed in the
jejunum (6 cats out of 9), followed by duodenum (2) and
ileum (1).
Median of FCEAI score obtained by LGAL group was
11 (range = 5–14) and IBD group was 9 (range = 4–12)
corresponding to moderate CE, but no statistical signifi-
cant difference was found (p = 1.000) (Table 1).
According to the WSAVA template, IBD group
showed a significant statistically higher score of morpho-
logical and inflammatory changes compared to the con-
trol group (p = 0.011, Table 1 and Fig. 2). Considering the
MWSAVA score, that only includes the morphological
features of the WSAVA template, LGAL group presented
a significantly higher value than the IBD (p = 0.011) and
control group (p < 0.001, Table 1 and Fig. 2). No signifi-
cant difference was found between IBD and control group
according to the MWSAVA score (p = 0.156, Table 1 and
Fig. 2). No lineal correlation was found between FCEAI
and total WSAVA, and MWSAVA scores (p > 0.05).
COX-2 epithelial immunoexpression was observed in
all studied cats, except 3 SC that belong to the control
group. Regarding the intensity of expression, 82% of cats
with IBD (9 out of 11) and 67% with LGAL (6 out of 9
cats) presented a marked intensity; remaining cats pre-
sented a moderate intensity. No significant difference
was detected between these groups (p = 1.000, Table 1).
Sixty-three per cent of cats from the control group
showed a moderate epithelial COX-2 intensity, but the
other ones did not present staining as mentioned above.
Furthermore, control group presented lower intensity in
comparison with the IBD (p = 0.001) and LGAL group
(p = 0.008, Table 1 and Fig. 2). Regarding the percentage
of cells, all cats from the IBD, 67% (6 out of 9) from the
LGAL and 63% (5 out of 8) from the control group showed
immunolabelling in more than 60% of the enterocytes, and
no statistically significant difference was observed concer-
ning to staining grade (p = 0.081, Table 1). COX-2 immu-
noexpressions are presented in Fig. 3a, b, c and d.
COX-2 expression at the LP was absent in all cats
from the control and IBD group (Table 1). In the LGAL
group, 2 cats presented moderate intensity and 1 cat a
marked intensity immunolabelling of neoplastic, how-
ever the immunoreactivity was presented in less than
10% of cells (Table 1 and Fig. 4a, b and c). Regardless,
no statistical significant differences were observed ac-
cording to intensity, staining grade and final score of
COX-2 expression at the LP between the three groups
(p > 0.05, Table 1).
Statistically significant lineal correlations were not ob-
served between epithelial or LP COX-2 expression and
FCEAI and histological alterations (p > 0.05; Spearman’s
ρ < 0.354).
Discussion
The population of animals used in the present study
confirmed previous findings showing that IBD affects
younger cats compared to AL, although overlap was
present. Male cats were overrepresented in LGAL group
as well as DSH cats in both studied groups in agreement
to previous reports [1–6, 16, 31].
Lymphoplasmacytic inflammation has been the most
common inflammatory pattern defined in cats with IBD
Table 1 FCEAI, modified and total WSAVA scores and COX-2 immunoexpression of Control, IBD and LGAL group












Control (median) – 0a 1a 2a 4a 8a 0a 0a 0a
IBD (median) 9a 1a 5b 3b 4a 12a 0a 0a 0a
LGAL (median) 11a 2b – 3b 4a 12a 0a 0a 0a
FCEAI feline chronic enteropathy activity index, WSAVA world small animal veterinary association; % percentage, LP lamina propria, IBD inflammatory bowel
disease, LGAL low grade alimentary lymphoma, − non score. Different letters show a significant difference (p < 0.05)
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and was localized most frequently in duodenum [6, 15, 36].
Duodenum is the most common GI segment evaluated,
but it is unlikely that IBD is restricted to this segment.
This location is probably overrepresented due to limita-
tions of endoscopy to obtain samples from lower small
intestine segments. Furthermore, FTBs are likely more
obtained from the duodenum as well than the jejunum
and ileum like the present study. According to previous
reports, T cell LGAL was more frequently localized in
the jejunum [5, 6, 11, 16, 37].
In contrast to our findings, a study in cats found cor-
relation between the WSAVA template and the FCEAI
[2], however no correlation was observed in studies per-
formed in dogs [1, 29, 38]. These discrepancies might be
due to the FCEAI was calculated retrospectively in most
of the cats. Furthermore, pancreatitis and hypocobalami-
naemia that could worsen clinical signs, was not com-
pletely ruled out. Also, in the present study we used
FTB from different intestinal segments that have been
evaluated by a single pathologist, which might have in-
fluenced WSAVA scores.
Maunder and colleagues [31] observed severe duo-
denal morphological changes applying the MWSAVA
scoring in LGAL and herein moderate changes were
found. Nevertheless, a significant difference was ob-
served between LGAL and IBD group in the present
study regarding MWSAVA scoring. Further studies are
needed to determinate whether this histological scoring
might help to differentiate between CE.
To our knowledge, this is the first report regarding
COX-2 expression in the intestinal epithelium and LP of
cats with IBD and LGAL. COX-2 is classically considered
an inducible enzyme, but it is also considered a
constitutive enzyme expressed in the GI tract [39]. More-
over, COX-2 products might be involved in maintaining
the integrity of intestinal mucosa [39]. Differences be-
tween species have been described about epithelial COX-2
expression along the GI tract in normal individuals. COX-
2 is expressed in the ileocoecal junction and colon in ro-
dents, in all the GI tract in dogs and in the stomach and
colon in humans [40–47]. In the present study, cats of the
control group presented epithelial COX-2 expression in
duodenum, jejunum and ileum (data not shown). There-
fore, this supports the need of more studies to clarify
COX-2 expression and role in normal individuals.
Regarding immunoreactivity in healthy feline GI tract,
only one study described COX-2 immunoexpression in
basal granulated cells of the epithelium using a polyclonal
antiprostaglandin H synthetase-2 (COX-2) human C
terminus antibody [48]. Some differences may be found
depending on the antibody used, in our study, immunola-
belling was found in the cytoplasm of the enterocytes in 5
cats of the control group (3 HCC and 2 SC). The discord-
ance on inmunoexpression may be explained by the differ-
ent anti-reagent used, or different affinity of the antibody,
however the antibody used herein was previously used in
cats [33–35, 45, 46, 49–51]. The presence of COX-2 posi-
tive and negative enterocytes in SC of the control group
might be explained by the degree of epithelial autolysis in
the samples. However, SC were necropsied within 1 h.
Even though epithelial autolysis was not observed in the
histopathology, molecular autolysis cannot be totally ruled
out that could influence on the COX-2 expression. An-
other possible explanation is the individual variability, it
has been demonstrated that only 50 to 80% of healthy
humans presents COX-2 expression in colon and stomach
Fig. 2 (left) WSAVA scores comparison between Control (Ctrl) and IBD group (*: significant difference (p < 0.05) between Control and IBD group),
(center) modified WSAVA scores comparison between Control, IBD and LGAL group (*: significant difference (p < 0.05) between Control and LGAL
group; between IBD and LGAL group) and (right) COX-2 intensity in the epithelium (*: significant difference (p < 0.05) between Control and IBD
group; between Control and LGAL group). Box plots represent median, 25th percentil, 75th percentil, maximum and minimum. WS AVA : world
small animal veterinary association; IBD: inflammatory bowel disease; LGAL: low grade alimentary lymphoma; COX-2: cyclooxygenase 2
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[45–47, 52]. Further studies with larger number of cats
are needed to obtain conclusions about normal COX-2
expression in the GI tract.
Epithelial intensity immunoexpression in IBD and
LGAL groups was significantly higher in comparison
with control group though no statistical difference was
found between the group of cats with IBD and LGAL.
Higher epithelial COX-2 immunolabelling has been re-
ported in humans with gastritis induced by Helicobacter
pylori, ulcerative colitis or Crohn’s disease compared to
normal epithelium. These observations agree with the
present study [45–47, 49, 52]. The increased COX-2 ex-
pression may be due to GI epithelial ulceration, however
in our study only 2 cats with LGAL presented epithelial
ulceration (data not shown) [45, 49]. Furthermore, it has
been described that COX-2 expression increases after
feeding in feline duodenum, but this is unlikely since the
cats used in the present study were fasted for anaesthetic
procedure or were anorectics [48]. Increased mucosal
levels of prostaglandin E2 in humans and interleukin-1β
Fig. 3 a Absence of COX-2 immunolabelling in the apical membrane of the epithelium from duodenum of a sick cat from the control group
(score 0); scale bar, 200 μm. b Moderate epithelial COX-2 immunoexpression of the apical membrane of enterocytes from the duodenum of
healthy control cats (score 2); scale bar, 100 μm. c Marked epithelial COX-2 labelling of the apical membrane of enterocytes from the jejunum of
severe lymphoplasmacytic enteritis (score 3); scale bar, 100 μm. d Marked epithelial COX-2 labelling of the apical membrane of enterocytes from
the jejunum of severe lymphoplasmacytic enteritis (score 3); scale bar, 100 μm
Fig. 4 a No expression of COX-2 at the neoplastic lymphocytes at the lamina propria of a low grade alimentary lymphoma (intensity 0); scale bar,
100 μm. b Moderate COX-2 expression of a few neoplastic cells at the lamina propria (black arrows) and enterocytes with marked reactivity (white
arrows) from a cat with low grade alimentary lymphoma (intensity 2); scale bar, 50 μm. c Marked expression of COX-2 at some neoplastic lymphocytes
at the lamina propria (black arrows) in a cat with low grade alimentary lymphoma (intensity 3); scale bar, 100 μm
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in dogs with IBD and food responsive diarrhoea have
been linked to an increased COX-2 immunoexpression
or upregulation [44, 49]. Based on these studies, it has
been suggested that cytokines and prostaglandins induced
by an inflammatory response increase COX-2 in the intes-
tinal mucosa as a protective mechanism [44, 49]. Regard-
ing LP, no expression was found in any cat from control
or IBD groups. At the same time, the normal feline lymph
node did not presented COX-2 expression (data not
shown), as previously described in dogs [53]. In humans
with IBD, macrophages and polymorphs are stained by
COX-2 at the LP [46, 47, 49, 52, 54]. However, those in-
flammatory cells are not present in feline IBD, and prob-
ably for this reason immunolabelling was not found in our
cases. Association between COX-2 upregulation and de-
velopment of lymphoma, as occurs in some tumours, re-
mains unknown but COX-2 overexpression is associated
with cell proliferation and angiogenesis [50, 51, 55, 56]. In
this study, only 3 cats with LGAL presented COX-2 ex-
pression in lymphoid tumour cells. Conversely, Beam and
colleagues [26] did not find COX-2 immunoexpression in
6 cats with AL. This disagreement may be due to a differ-
ent immunohistochemical technique. A recent report
stated that 15% of canine lymphoma presented COX-2
overexpression which agrees with the present findings
[57]. However, other studies in canine lymphoma did not
find COX-2 immunoreactivity [53, 56]. Furthermore, stud-
ies in humans revealed that most of non-Hodgkin’s
lymphoma (> 50% of cases) had COX-2 expression by
tumour cells [58–60]. Thus, COX-2 upregulation in
lymphomas has been associated with the aggressiveness,
relapsed, worst response to therapy and less overall sur-
vival [58–61]. This latter could not be determined in our
study because not all cats had available follow-up. Pro-
spective studies are needed in cats with different lymph-
oma phenotypes and anatomical locations to further
understand the role of COX-2 in feline AL. No correla-
tions were observed between FCEAI, histological alter-
ations, IBD and LGAL with COX-2 expression. Similar
results have been obtained in canine IBD, and human
lymphoma and IBD [44, 46, 58–60].
This study presented some limitations, most of the
cases were recruited retrospectively and FCEAI was cal-
culated by record data or owner interview by phone
calls, therefore subjectivity may be an uncontrolled vari-
able. Although intraobserver variation among histopath-
ologic evaluations of intestinal tissues were not present
due to one pathologist evaluated all biopsies, an intraob-
server variation could have existed [62]. Cases of triaditis
were not included, however feline specific pancreatic lip-
ase was not available in all cases and pancreatitis was
ruled out by ultrasound. Moreover, all histopathological
diagnosis was made prior to the availability of polymer-
ase chain reaction for antigen receptor rearrangements;
thereby a misdiagnosis could have occurred. However,
FTB was available in almost all cats and immunohisto-
chemistry was performed by increasing the sensitivity
and specificity [16].
Conclusions
Increased COX-2 intensity at the epithelial cells observed
in cats with IBD and LGAL may be secondary to the in-
flammatory response or a protective function in the intes-
tinal reparation. COX-2 expression at the LP was presented
in only 33% of LGAL cats, thus further investigation of
COX-2 expression in feline AL are needed to clarify its im-
portance in prognostic and response to therapy.
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